Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers

The meaning and use of the area under a receiver operating characteristic (ROC) curve.

1982 • 20,275 citations

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

1987 • 11,429 citations

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

1989 • 6,734 citations

A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1

1994 • 5,994 citations

Basic principles of ROC analysis

1978 • 5,844 citations

BRCA1 Mutations in Primary Breast and Ovarian Carcinomas

1994 • 1,205 citations

Accumulation of p53 Tumor Suppressor Gene Protein: An Independent Marker of Prognosis in Breast Cancers

1992 • 757 citations

Prediction of Relapse or Survival in Patients with Node-Negative Breast Cancer by DNA Flow Cytometry

1989 • 571 citations

The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation.

1995 • 482 citations

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

1994 • 467 citations

Practice Guidelines, a New Reality in Medicine

1992 • 416 citations

Measuring quality of life in cancer patients.

1989 • 335 citations

A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening

1995 • 329 citations

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

1995 • 312 citations

Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study

1985 • 264 citations

Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients.

1992 • 135 citations

Criteria for prognostic factors and for an enhanced prognostic system

1993 • 127 citations

An exaltation of experts: Concerted efforts in the standardization of immunohistochemistry

1994 • 116 citations

CEA Monitoring Among Patients in Multi-institutional Adjuvant G.I. Therapy Protocols

1982 • 111 citations

Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.

1992 • 96 citations

Artificial neural networks for cancer research: Outcome prediction

1994 • 86 citations

A demonstration that breast cancer recurrence can be predicted by Neural Network analysis

1992 • 85 citations

TUMOR MARKERS IN TESTIS CANCER

1993 • 76 citations

How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer

1993 • 72 citations

Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study.

1991 • 70 citations

When is a prognostic factor useful? A guide for the perplexed.

1991 • 69 citations

A retrospective and prospective study of serial CEA determinations in the early detection of recurrent colon cancer

1979 • 59 citations

Circulating Tumor Markers in Breast Cancer

1989 • 54 citations

Tumor markers for breast cancer

1993 • 49 citations

Surrogate endpoints in clinical trials: Ophthalmologic disorders

1989 • 47 citations

Serum Markers in Germ Cell Neoplasms

1991 • 39 citations

Preservation of Estrogen Receptor in Paraffin Sections

1994 • 31 citations

Lung cancer: A review of current therapeutic modalities

1992 • 28 citations

Neural network analysis of DNA flow cytometry histograms

1993 • 28 citations

Carcinoembryonic antigen immunocytochemistry in primary breast cancer

1989 • 27 citations

The National Cancer Institute and Guideline Development: Lessons From the Breast Cancer Screening Controversy

1994 • 24 citations

Serum Tumor Marker Half-Life during Chemotherapy in Patients with Germ Cell Tumors

1994 • 13 citations

Neoadjuvant and adjuvant therapy in the management of locally advanced non-small-cell lung cancer

1993 • 5 citations

Markers of Risk for Human Malignancies

1994 • 3 citations